Shahadat Ahmed

This inventor holds 9 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents. Top assignees: Dr. Reddy's Laboratories, Incorporated, Other. Active years: 2015-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shahadat Ahmed. Retrieved from https://idiyas.com/inventor/shahadat-ahmed

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 5.6

ph-index = 2

Forward Citations = 25(Granted Patents)

Location History:

Bangalore, IN (US) (2016)
Bengaluru, IN (2015 - 2019)

Company Filing History:

8 out of 187

Dr. Reddy's Laboratories, Incorporated

patents

1 out of 834,570

Other

patents

Years Active: 2015-2019

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10344031 - Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors (2019-07-09),

2. 10047087 - Substituted pyrazolo[1,5-A] pyridine as tropomyosin receptor kinase (TrK) inhibitors (2018-08-14),

3. 9782391 - Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors (2017-10-10),

4. 9670207 - Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors (2017-06-06),

5. 9402833 - Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors (2016-08-02),

6. 9394305 - Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors (2016-07-19),

7. 9289419 - Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors (2016-03-22),

8. 9045479 - Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors (2015-06-02),

9. 9045478 - Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors (2015-06-02),

Title: Shahadat Ahmed: Innovator in Pharmaceutical Chemistry

Introduction

Shahadat Ahmed is a prominent inventor based in Bengaluru, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for therapeutic applications. With a total of nine patents to his name, he has established himself as a key figure in innovation within the industry.

Latest Patents

Among his latest patents are two notable inventions related to substituted pyrazolo[1,5-a] pyridine compounds. These compounds are recognized for their potential as tropomyosin receptor kinase (Trk) inhibitors. The applications detail methods of making these compounds and their use in pharmaceutical compositions, highlighting their importance in targeting the Trk family protein kinase.

Career Highlights

Shahadat has worked with Dr. Reddy's Laboratories, a leading pharmaceutical company known for its commitment to innovation and quality. His work there has contributed to advancements in drug development and therapeutic solutions.

Collaborations

Some of his notable coworkers include Pradip Kumar Sasmal and Ashok Tehim, who have collaborated with him on various projects, enhancing the scope and impact of their research.

Conclusion

Shahadat Ahmed's contributions to pharmaceutical chemistry through his innovative patents and collaborations underscore his role as a significant inventor in the field. His work continues to influence the development of new therapeutic agents.

Profile summary based on public USPTO records.